# Thesis Proposal

Predictive Modeling with Imbalanced Data?

*Alyssa Forber*

*Susan Calcaterra, Elizabeth Juarez-Colunga, Kathryn Colborn*

*November 30, 2017*

**Abstract**

Do I need an abstract?

## Introduction

- Don't go into background problem too much? (for stats paper)

- Do I open on the imbalanced learning problem?

- How much to describe the dataset?

- start with opioid problem

- how much increase in opioid use

- how need to identify patients at increased risk is immediate

- this presents a statistical problem in classifying patients when identifying a rare outcome

- cite some other issues in health with rare outcomes and what people have done

- give fair bit of background (stats in medical, etc) find where people try to predict rare outcomes

- hopefully no ones done exactly what we've done

- no one's explored the tradeoffs of cut-points and sampling, what we've sought to do in order to achieve best prediction

- last paragraph, we sought to identity patients at risk for COT at a safety hospital at Denver, predictive performance, few sentences on what we're doing and what methods and dataset

Predictive modeling with imbalanced data has been found to have report low sensitivity (reference?). To combat this issue of overlooking many true postitives,

To illustrate this issue, we are using electronic health record data from 2008 to 2014 of patients for patients with chronic opioid therapy (COT). Five percent of the 27,705 patients were reported with the outcome, which was defined as receipt of $\geq$ 90-day supply of opioids

with $< 30$-day gap in supply over a 180-day period or receipt of $\geq 10$ opioid prescriptions over one year.

## Methods

Subtitle Data - start with describing the data but no statistics, Denver health, years,

Statistical Methods sub

The analysis was done in RStudio version 1.1.383.

We used a roughly 2/3rd temporal split of the data to create training and testing datasets, where years 2008-2011 were used to train (65%), and 2012-2014 were used to test (35%).

The model used for this analysis was cross validated lasso regression. This was chosen as it has been found to perform better predictor selection than stepwise selection (reference on this?), and as we were not interested in having interpretable coefficients.

The predictors were first narrowed from ? to 35 (?) based on clinical relevance (Can I reference the paper that is under submission since that goes into more details? Is it even necessary).

We first evaluated the prediction performance of the dataset without sampling to see the effects of the imbalanced data on the accuracy, sensitivity, and specificity. This was to serve as a baseline to compare with the techniques available to mitigate the issue of poor sensitivity. The predicted probability cut-point used here was rounding at the standard 0.5 that would be appropriate in balanced datasets.

The first approach used to improve performance was to choose a more informed probability cut-point for the data. This was done using the Youden Index, which finds the maximum of the receiver operating characteristic (ROC) curve (reference here!) with the pROC package (do I need to say this?).

The second approach was through sampling the dataset. Three types of sampling methods were compared–down sampling, up sampling, and Synthetic Minority Over-sampling Technique (SMOTE). Down sampling takes a random sample from the majority class, in this case those who are not classified as having chronic opioid therapy, in order to match the size of the minority class (reference?). Up sampling does the reverse to take random samples of the minority class in order to match the majority (reference?). SMOTE combines sampling both from the majority and minority, but instead of taking identical copies of the minority it creates synthetic observations (reference). For each of the three sampling techniques, the probability cut-point was optimized using the Youden Index as before.

## Results

Results is strictly results, no interpretation

Report the results, but don't go into what is better

As expected, without using an optimized cut-point or sampling technique, the sensitivity of the model was extremely poor at 8%, with high specificity and accuracy (99% and 96%). Simply choosing a more informed probability cut-point to 0.043 instead of 0.5 improved the sensitivity to 85% and brought the specificity down to 73%. This cut-point is intuitive as the outcome is present at 5% in the dataset, which would be consistent with a 0.5 cutoff in a evenly split dataset. The up and down sampled datasets both showed the same improved sensitivity with probability cut-points at about 0.4, also with close specificities of 74 and 73%. SMOTE on the other hand, resulted in 74% sensitivity and 84% specificity. However, there were improvements in accuracy for SMOTE at 86% as compared to the other three approaches, which had accuracies at 86-87%.

There was no change to the negative predicted value across the approaches, and a decrease in positive predicted value. In terms of the ROC analysis, the area under of the curve for each approach was about the same at 86-87%. See Table 2 for full results for the cut-point, sensitivity, specificity, accuracy, negative predicted value, positive predicted value, and area under the curve.

## Discussion

- there do appear to be variables iwth strong associations, but the question of model choice depends on what method- get different vars from lasso if you're doing cutpoint or sampling

sampling gives a case control in your data and I think should give fewer variables (LOOK AT HOW MANY ARE LEFT IN, REMEMBER SOME ARE MULTIPLE CATEGORIES JUST COUNT ONE AND PUT INTO STATS TABLE)

trade offs to discuss with physician, at what point do the sens, spec need to be

Across the different samples, we saw similar improvements for sensitivity.

- Again are we really comparing cut-points and sampling if we do both in second approach? What do we say we're finding here

## Conclusion

## Acknowledgments

Do I just include committee members as authors and then acknowledge the University?

KL Colborn PhD

E Juarez-Colunga PhD

SL Calcaterra MD, MPH

Table 1:

| Variable | Yes COT 1,457 (5%) | No COT 26,248 (95%) | p-value |
|---|---|---|---|
| Age 15-35 | 10% | 22% | <.001 |
| Age 45-55 | 35% | 24% | <.001 |
| Age 55-65 | 28% | 21% | <.001 |
| Discount payment or Medicaid | 76% | 61% | <.001 |
| History of chronic pain | 76% | 53% | <.001 |
| Discharge diagnosis chronic pain | 50% | 29% | <.001 |
| Surgical patient | 48% | 39% | <.001 |
| Past year: | | | |
| Benzodiazepine | 16% | 5% | <.001 |
| Non-opioid analgesics | 25% | 9% | <.001 |
| Number of opioid prescriptions: | | | |
| 0 | 38% | 80% | |
| 1 | 17% | 11% | |
| 2 | 14% | 4% | |
| 3 | 9% | 2% | |
| 4-9 | 23% | 3% | <.001 |
| Receipt of opioid at discharge | 56% | 28% | <.001 |
| MME per hospital day > 10 | 80% | 52% | <.001 |

Table 2:

| Data | Threshold | Specificity | Sensitivity | NPV | PPV | Accuracy | AUC | Covariates |
|---|---|---|---|---|---|---|---|---|
| Unsampled 0.5 | 0.5 | 99 | 8 | 96 | 35 | 96 | 86 | 31 |
| Unsampled | 0.043 | 73 | 85 | 99 | 12 | 73 | 86 | 31 |
| Down sampled 0.5 | 0.5 | 81 | 75 | 99 | 15 | 81 | 86 | 34 |
| Down sampled | 0.401 | 73 | 85 | 99 | 12 | 74 | 86 | 34 |
| Up sampled 0.5 | 0.5 | 82 | 75 | 99 | 15 | 82 | 87 | 34 |
| Up sampled | 0.399 | 74 | 85 | 99 | 12 | 74 | 87 | 34 |
| SMOTE 0.5 | 0.5 | 86 | 71 | 99 | 17 | 85 | 86 | 33 |
| SMOTE | 0.472 | 84 | 74 | 99 | 17 | 84 | 86 | 33 |

# References

ROC, Youden, SMOTE, LASSO, cross-validation Chronic Opioid Therapy, up-sampling, down-sampling

A Statistical Model for Prediction of Future Chronic Opioid Use among Hospitalized Patients

# Appendix

Include full table 1? Yes include the full table before but pull out some of the ones from the smaller table to quote

Among these set of varaibles, which ones are most important in classying. Aall it supervised learning problem (because observed outcome)

**Unsampled ROC Curve**



Sensitivity (y-axis) vs Specificity (x-axis)
0.043 (0.727, 0.854)
0.500 (0.993, 0.088)

Table 1

|  | Total (N=27,705) | Chronic Opioid Use | | P-Value |
|  |  | Yes (N=1,457) | No (N=26,248) | |
|---|---|---|---|---|
| Gender, n (%) |  |  |  |  |
| Female | 12,933 (46.7) | 652 (44.7) | 12,281 (46.8) | 0.13 |
| Race, n (%) |  |  |  |  |
| Hispanic | 10,798 (39.0) | 580 (39.8) | 10,218 (38.9) | 0.01 |
| Non-Hispanic White | 10,645 (38.4) | 555 (38.1) | 10,090 (38.4) |  |
| African American | 4,842 (17.5) | 273 (18.7) | 4,569 (17.4) |  |
| Other or Unknown | 1,420 (5.1) | 49 (3.4) | 1,371 (5.2) |  |
| Age at Index Admission (Years), n (%) |  |  |  |  |
| 15-<35 | 6,017 (21.7) | 150 (10.3) | 5,867 (22.4) | <0.0001 |
| 35-<45 | 4,734 (17.1) | 267 (18.3) | 4,467 (17.0) |  |
| 45-<55 | 6,919 (25.0) | 506 (34.7) | 6,413 (24.4) |  |
| 55-<65 | 5,880 (21.2) | 400 (27.5) | 5,480 (20.9) |  |

|  |  | Chronic Opioid Use |  | P-Value |
|---|---|---|---|---|
| 65-<75 | 2,745 (9.9) | 110 (7.5) | 2,635 (10) |  |
| 75-↓85 | 1,410 (5.1) | 24 (1.6) | 1,386 (5.3) |  |
|  |  |  |  |  |
| Mean (SD) | 48.1 (16.0) | 50.2 (11.6) | 48.0 (16.2) |  |
| Median (25th, 75th) | 49 (37, 59) | 51 (43, 58) | 49 (36, 59) |  |
| Insurance Status, n (%) |  |  |  |  |
| Discount Payment Plan* | 8,499 (30.7) | 576 (39.5) | 7,923 (30.2) | <0.0001 |
| Medicaid | 8,575 (31.0) | 531 (36.4) | 8,044 (30.6) |  |
| Medicare | 6,260 (22.6) | 259 (17.8) | 6,001 (22.9) |  |
| Commercial | 2,402 (8.7) | 50 (3.4) | 2,352 (9.0) |  |
| Other/Unknown/Self-Pay | 1,969 (7.1) | 41 (2.8) | 1,928 (7.3) |  |
| Three Year History of, n (%) |  |  |  |  |
| Tobacco Use Disorder | 9,682 (34.9) | 716 (49.1) | 8,966 (34.2) | <0.0001 |
| Alcohol Use Disorder | 7,167 (25.9) | 408 (28.0) | 6,759 (25.8) | 0.06 |
| Stimulant Use Disorder | 1,719 (6.2) | 118 (8.1) | 1,601 (6.1) | 0.003 |
| Opioid Use Disorder | 672 (2.4) | 44 (3.0) | 628 (2.4) | 0.13 |
| Chronic Pain | 14,914 (53.8) | 1,105 (75.8) | 13,809 (52.6) | <0.0001 |
| Acute Pain | 10,073 (36.4) | 611 (41.9) | 9,462 (36.0) | <0.0001 |
|  |  |  |  |  |
| Top 3 Mental Health Disorders, n (%) |  |  |  |  |
| Depression | 6,318 (22.8) | 491 (33.7) | 5,827 (22.2) | <0.0001 |
| Anxiety Disorder | 3,677 (13.3) | 265 (18.2) | 3,412 (13.0) | <0.0001 |
| Bipolar Disorder | 2,362 (8.5) | 135 (9.3) | 2,227 (8.5) | 0.3 |

|  |  | Chronic Opioid Use |  | P-Value |
|---|---|---|---|---|
| Any Mental Health Disorder n (%) | 9,805 (35.4) | 634 (43.5) | 9,171 (34.9) | <0.0001 |
| **Top 3 Chronic Medical Conditions, n (%)** |  |  |  |  |
| Hypertension | 11,799 (42.6) | 773 (53.1) | 11,026 (42.0) | <0.0001 |
| Respiratory Disease | 7,060 (25.5) | 444 (30.5) | 6,616 (25.2) | <0.0001 |
| Diabetes Mellitus | 5,701 (20.6) | 376 (25.8) | 5,325 (20.3) | <0.0001 |
| Any Chronic Medical Condition, n (%) | 17,535 (63.3) | 1,102 (75.6) | 16,433 (62.6) | <0.0001 |
| **Charlson Comorbidity Index from 3 Year Diagnosis History** |  |  |  |  |
| Mean (SD) | 1.9 (2.2) | 2.4 (2.5) | 1.9 (2.2) | <0.0001 |
| Median (25th, 75th) | 1 (0, 3) | 2.0 (1, 3) | 1.0 (0, 3) |  |
| **Discharge Diagnoses, n (%)** |  |  |  |  |
| Chronic Pain_ | 8,346 (30.1) | 729 (50.0) | 7,617 (29.0) | <0.0001 |
| Acute Painŕ | 4,586 (16.6) | 255 (17.5) | 4,331 (16.5) | 0.32 |
| Neoplasm¤ | 1,447 (5.2) | 170 (11.7) | 1,277 (4.9) | <0.0001 |
| **Top 3 Surgical Procedures During Initial Hospitalization, n (%)** |  |  |  |  |
| Digestive System | 3,437 (12.4) | 225 (15.4) | 3,212 (12.2) | <0.001 |
| Musculoskeletal System | 3,037 (11.0) | 258 (17.7) | 2,779 (10.6) | <0.0001 |
| Cardiovascular System | 2,312 (8.3) | 157 (10.8) | 2,155 (8.2) | <0.001 |
| Patients Who Had Surgical Procedure During Index Hospitalization, n (%) | 10,956 (39.5) | 700 (48.0) | 10,256 (39.1) | <0.0001 |
| **Number of Healthcare Encounters in the One Year Preceding the Index Admission, n (%)** |  |  |  |  |
| 0 | 23,280 (84.0) | 1,196 (82.1) | 22,084 (84.1) | 0.03 |

|  | | Chronic Opioid Use | | P-Value |
| --- | --- | --- | --- | --- |
| 1 | 3,413 (12.3) | 197 (13.5) | 3,216 (12.3) | |
| 2+ | 1,012 (3.7) | 64 (4.4) | 948 (3.6) | |
| | | | | |
| Mean (SD) | 0.2 (0.6) | 0.2 (0.7) | 0.2 (0.6) | |
| Median (25th, 75th) | 0.0 (0, 0) | 0.0 (0, 0) | 0.0 (0, 0) | |
| Past Year Benzodiazepine Receipt, n (%) | 1,606 (5.8) | 227 (15.6) | 1,379 (5.3) | <0.0001 |
| Past Year Receipt of Non-Opioid Analgesics (NSAIDs, neuropathic agents, topical capsaicin & lidocaine), n (%) | | | | |
| | 4,875 (17.6) | 620 (42.6) | 4,255 (16.2) | <0.0001 |
| Past Year Number of Opioid Prescriptions Filled, n (%) | | | | |
| 0 | 21,543 (77.8) | 549 (37.7) | 20,994 (80.0) | <0.0001 |
| 1 | 3,167 (11.7) | 249 (17.1) | 2,918 (11.1) | |
| 2 | 1,331 (4.8) | 197 (13.5) | 1,134 (4.3) | |
| 3 | 646 (2.3) | 132 (9.1) | 514 (2.0) | |
| 9-Apr | 1,018 (3.7) | 330 (22.6) | 688 (2.6) | |
| Receipt of Opioid at Discharge, n (%) | 8,028 (29.0) | 817 (56.1) | 7,211 (27.5) | <0.0001 |
| Milligrams of Morphine Per Hospital Day, n (%) | | | | |
| 0 | 9,655 (34.8) | 189 (13.0) | 9,466 (36.1) | <0.0001 |
| 0.01 < 10 | 3,320 (12.0) | 108 (7.4) | 3,212 (12.2) | |
| 10 < 51 | 7,337 (26.5) | 490 (33.6) | 6,847 (26.1) | |
| 51 < 100 | 4,413 (15.) | 371 (25.5) | 4,042 (15.4) | |
| 100+ | 2,980 (10.8%) | 299 (20.5) | 2,681 (10.2) | |

|  |  | Chronic Opioid Use |  | P-Value |
| --- | --- | --- | --- | --- |
| Mean (SD) | 37.7 (65.4) | 64.4 (76.7) | 36.2 (64.4) |  |
| Median (25th, 75th) | 12.5 (0, 54.7) | 45.5 (14.3, 90.2) | 10.8 (0, 52.2) |  |
| Length of Hospital Stay (days) |  |  |  |  |
| 1 | 8,449 (30.0) | 383 (26.3) | 8,066 (30.7) | 0.0003 |
| 2 | 5,655 (20.4) | 282 (19.4) | 5,373 (20.5) |  |
| 5-Mar | 7,801 (28.2) | 450 (30.9) | 7,351 (28.0) |  |
| 6+ | 5,800 (20.9) | 342 (23.5) | 5,458 (20.8) |  |
|  |  |  |  |  |
| Mean (SD) | 4.7 (9.0) | 4.9 (7.7) | 4.6 (9.1) |  |
| Median (25th, 75th) | 2 (1, 5) | 3 (1, 5) | 2 (1, 5) |  |
| Number of Subsequent Hospitalizations within 12 Months post Hospital Discharge |  |  |  | $<0.001$ |
| Mean (SD) | NA | 1.48 (2.20) | 0.54 (1.21) |  |
| Median (25th, 75th) | NA | 1 (0,2) | 0 (0,1) |  |